Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.

Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T

Diabetes care1 Jul 2014Cited by 106 (Europe PMC)

PMID24929431DOI10.2337/dc13-3007PepBankPUB-24929431

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with HNF1A diabetes (MODY3), 6 weeks of liraglutide decreased fasting plasma glucose from baseline.
In plain wordsIn adults with HNF1A diabetes, fasting blood sugar fell after 6 weeks of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change from baseline
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up-titrated to 1.8 mg once daily · 6 weeksAs given in this study (human).
Measurements
FPG change
−1.6 mmol/L
liraglutide
Source sentences
Summary
FPG decreased during the treatment periods (-1.6 ± 0.5 mmol/L liraglutide [P = 0.012]
2 context sentences(design, population, supporting numbers)
Summary · context
received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections), in randomized order, in a double-blind, crossover trial.
Summary · context
Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1.8 mg once daily.
Report a problemFND-2492943101
02HumanRandomized controlled trialEfficacy outcome
In adults with HNF1A diabetes (MODY3), the fasting plasma glucose decrease did not differ between liraglutide and glimepiride.
In plain wordsIn adults with HNF1A diabetes, liraglutide and glimepiride lowered fasting blood sugar by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose, liraglutide versus glimepiride
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up-titrated to 1.8 mg once daily · 6 weeksAs given in this study (human).
Measurements
FPG change
−1.6 mmol/L
liraglutide
FPG change
−2.8 mmol/L
glimepiride
Source sentences
Summary
FPG decreased during the treatment periods (-1.6 ± 0.5 mmol/L liraglutide [P = 0.012] and -2.8 ± 0.7 mmol/L glimepiride [P = 0.003]), with no difference between treatments (P = 0.624).
2 context sentences(design, population, supporting numbers)
Summary · context
received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections), in randomized order, in a double-blind, crossover trial.
Summary · context
Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1.8 mg once daily.
Report a problemFND-2492943102
03HumanRandomized controlled trialEfficacy outcome
In adults with HNF1A diabetes (MODY3), postprandial plasma glucose responses were lower with liraglutide than at baseline.
In plain wordsIn adults with HNF1A diabetes, blood sugar after meals was lower on liraglutide than before treatment.
Peptide
Liraglutide
Outcome
DecreasePostprandial plasma glucose AUC versus baseline
Study
n = 16
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up-titrated to 1.8 mg once daily · 6 weeksAs given in this study (human).
Source sentences
Summary
Postprandial plasma glucose (PG) responses (total area under the curve) were lower with both glimepiride (2,136 ± 292 min × mmol/L) and liraglutide (2,624 ± 340 min × mmol/L) compared with baseline (3,127 ± 291 min × mmol/L; P < 0.001, glimepiride; P = 0.017, liraglutide), with no difference between…
2 context sentences(design, population, supporting numbers)
Summary · context
received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections), in randomized order, in a double-blind, crossover trial.
Summary · context
Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1.8 mg once daily.
Report a problemFND-2492943103
04HumanRandomized controlled trialEfficacy outcome
In adults with HNF1A diabetes (MODY3), postprandial glucose responses did not differ between liraglutide and glimepiride.
In plain wordsIn adults with HNF1A diabetes, after-meal blood sugar was similar on liraglutide and on glimepiride.
Peptide
Liraglutide
Outcome
No significant changePostprandial plasma glucose AUC, liraglutide versus glimepiride
Study
n = 16
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up-titrated to 1.8 mg once daily · 6 weeksAs given in this study (human).
Source sentences
Summary
Postprandial plasma glucose (PG) responses (total area under the curve) were lower with both glimepiride (2,136 ± 292 min × mmol/L) and liraglutide (2,624 ± 340 min × mmol/L) compared with baseline (3,127 ± 291 min × mmol/L; P < 0.001, glimepiride; P = 0.017, liraglutide), with no difference between…
2 context sentences(design, population, supporting numbers)
Summary · context
received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections), in randomized order, in a double-blind, crossover trial.
Summary · context
Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1.8 mg once daily.
Report a problemFND-2492943104
05HumanRandomized controlled trialSafety outcome
In adults with HNF1A diabetes (MODY3), one hypoglycemia episode occurred during liraglutide treatment versus eighteen during glimepiride treatment.
In plain wordsIn adults with HNF1A diabetes, low blood sugar happened once on liraglutide and eighteen times on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemia episodes
Study
n = 16
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
up-titrated to 1.8 mg once daily · 6 weeksAs given in this study (human).
Source sentences
Summary
Eighteen episodes of hypoglycemia (PG ≤3.9 mmol/L) occurred during glimepiride treatment and one during liraglutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections), in randomized order, in a double-blind, crossover trial.
Summary · context
Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1.8 mg once daily.
Report a problemFND-2492943105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3NCT01610934

The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)

University Hospital, Gentofte, Copenhagenn = 15Aug 2012 to Aug 2013

Maturity-onset Diabetes of the Young

Trial page ClinicalTrials.govUpdated 5 Sept 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.